Everest Organics Secures Korean Drug Master File Approval for Rabeprazole Sodium API

Everest Organics Limited has achieved a significant milestone by obtaining Drug Master File (DMF) approval from South Korea for its Rabeprazole Sodium API. This approval expands the company's global footprint and enhances its position in the Asian pharmaceutical market. Rabeprazole Sodium, a proton pump inhibitor used to treat various gastroenterological conditions, is a key product in Everest Organics' portfolio. The Korean DMF approval is expected to boost the company's export potential and revenue streams. This achievement aligns with Everest Organics' strategy to expand its presence in regulated markets and diversify its product offerings. The company continues to focus on research and development to introduce new products and improve existing processes.

 

Source: Everest Organics Limited Corporate Announcement